Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Chek Diagnostics
INDIANAPOLIS, May 6, 2014 /PRNewswire/ -- Chek Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow family of point-of-care diagnostic products, announced today that they have started shipping A1CNow+ systems to their distributor network. Just four months ago, Chek Diagnostics acquired the A1CNow family of products from Bayer Diabetes Care.
"A1CNow systems are important to healthcare providers and patients worldwide," said Robert Huffstodt, President and CEO of Chek Diagnostics. "So, it was critical for us to facilitate a seamless transition and deliver the products in a timely manner."
Ben Irvin, Director of A1CNow Research and Development, was a member of the team that developed the original A1CNow system in the early 2000s. "All of us in Sunnyvale, CA, are excited to be part of Chek Diagnostics. Their expertise in diagnostic device manufacturing, scientific knowhow, and established distribution network make this affiliation a perfect fit for the A1CNow family of products. We are also pleased that we were able to retain over 50 of our key people and that manufacturing and development will continue at the current plant in Sunnyvale."
Not only did Chek Diagnostics acquire a high-quality and well-known product family, the company also purchased a proven manufacturing facility and is pleased to also employ so many associates that have a deep institutional knowledge of the A1CNow technology.
"We are delighted to welcome these former Bayer A1CNow employees and their customers to the Chek Diagnostics family. This has been an extraordinarily fast and easy transition. We are proud to be shipping product this quickly," Huffstodt continued. "We know there is significant pent-up demand for the A1CNow+, and are pleased to be able to provide product without further delay."
A1CNow+ empowers healthcare professionals to provide individuals with an indicator of average blood glucose control for the past 2 to 3 months.
About Chek Diagnostics – Chek Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, Chek Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. Chek Diagnostics' products include the CardioChek systems and A1CNow point-of-care systems. The company also offers a variety of single and combination tests for lipids (cholesterols), glucose, and ketones, as well as the CardioChek Health Risk Assessment (HRA) software package. For more information, visit www.chekdiagnostics.com.
All trademarks used or mentioned in this release are protected by law.
©2012 PR Newswire. All Rights Reserved.